Clinical Trial

Study of ABO2102 in KRAS-Mutated Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label Phase 1 clinical study to evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics, as well as preliminary anti-tumor activity of ABO2102 as monotherapy and in combination among participants with solid tumors with KRAS mutations.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-07
Trial Details
NCT Number NCT07455617
Lead Sponsor Suzhou Abogen Biosciences Co., Ltd.
Collaborators: Abogen Biosciences (Shanghai) Co., Ltd
Conditions Advanced / Metastatic Solid Tumor
Enrollment 101 participants
Start Date 2026-03-24
Primary Completion 2029-06 (estimated)
Study Completion 2030-02 (estimated)
Updated on ClinicalTrials.gov 2026-04-06